Eculizumab use in a tertiary care nephrology center: data from the Vienna TMA cohort

CONCLUSIONS: In summary, eculizumab is the treatment of choice for cTMA patients that do not respond to plasma therapy. In patients with sTMA and C3G, the response rates to therapy are much lower and therefore, the decision to start therapy needs to be considered carefully.PMID:33599971 | DOI:10.1007/s40620-021-00981-8
Source: Journal of Nephrology - Category: Urology & Nephrology Authors: Source Type: research